Psychedelic-assisted therapy is an effective treatment for treatment-resistant depression

What's this about?

People disagree about whether psychedelic (mind-changing drug) therapy can help people with hard-to-treat depression. Most research looks at psilocybin, a drug from some mushrooms.

What supporters say

• Some studies found that psilocybin with talk support eased depression more than a very tiny dose.
• People sometimes felt better within days or weeks after one or a few guided sessions.
• Studies that combine many results found signs that these drugs can ease depression.
• Careful studies saw few serious harms after doctors screened and watched each person closely.

What critics say

• We do not yet know if the gains last for months or years.
• Most studies included only select adults in tightly watched settings.
• Some studies compared psilocybin with delayed care, not with a real drug or standard care.
• These tests cannot yet show that psilocybin works better than current depression treatments.

The bottom line

Psilocybin therapy shows real short-term promise for some adults with hard-to-treat depression. But we still need more research to know how well it works in daily care and how long benefits last.

Psychedelic-assisted therapy, especially treatment using psilocybin alongside psychological support, shows promising short-term benefits for adults with treatment-resistant depression. But the evidence does not yet prove that it works broadly, lasts over time, or outperforms established treatments in ordinary clinical practice.

The case for

The strongest evidence is that psilocybin-assisted therapy can reduce depression symptoms in the short term for some people whose condition has not improved with standard treatments. In a randomized phase 2b trial, patients with treatment-resistant depression who received a single 25-milligram dose of psilocybin with psychological support improved more than those given a very low dose. Another randomized study, using repeated doses alongside psychotherapy, also found antidepressant effects in this group. The improvement can begin within days or weeks, after only one or a few supervised sessions. 1 2

The results are not limited to one trial. Systematic reviews and meta-analyses have found an overall antidepressant effect across studies of psychedelic treatment for depression, including signs that higher doses are linked with greater improvement (see Figure 2). Reviews of randomized trials generally describe the treatment’s potential as promising. 3

There is also a broader signal in major depression, though the evidence there is not as directly relevant to treatment-resistant cases. One randomized study found greater short-term improvement with psilocybin-assisted therapy than with delayed treatment. However, delayed treatment is a weaker comparison than an active placebo or an established antidepressant treatment, so it cannot show whether psilocybin is better than current options (see Figure 1).

Within carefully run studies, serious harm appears uncommon among selected participants. Patients are screened in advance and receive preparation, monitoring and psychological support. Common short-term effects—including anxiety, changes in perception, nausea and changes in heart rate or blood pressure—usually pass. Reviews have found that serious psychiatric or behavioral events are rare in these controlled settings. 4

The case against

The central question is whether the results reflect a lasting, drug-specific effect—or the combined impact of psilocybin, intensive support and patients’ expectations. Psychedelic trials face an unusual problem: participants and researchers may often guess who received the active drug because its effects are so noticeable. That can weaken the “blinding” intended to keep expectations from shaping results. Expectations may affect who joins trials, how engaged they are in therapy, how they report symptoms and how assessors judge outcomes. 5

The evidence is also strongest in specialized research environments, not in routine care. Successful studies have typically involved carefully selected patients, extensive preparation, close observation and psychotherapy. They therefore provide less information about people excluded from trials, unsupervised use, repeated long-term treatment or rare harms. In the phase 2b trial, some participants reported suicidal thoughts or behavior, underscoring the need for continued safety assessment. 6 8

It is still unclear how long benefits last or whether treatment prevents relapse. The key treatment-resistant depression trial did not follow patients long enough to answer that question. A longer observational follow-up found continuing improvement for some people, but it had no comparison group and could be distorted by participants dropping out or by differences between those who stayed and those who did not. 7

Nor is there proof that psilocybin-assisted therapy is superior to other options for treatment-resistant depression, such as electroconvulsive therapy, ketamine, medication changes or psychotherapy. Existing comparisons are largely indirect, involving different patient groups, treatment settings and measures of success. UK guidance does not recognize it as a routine depression treatment, while US regulators have highlighted the need for better studies of blinding, psychotherapy standards, dosing, safety and long-term outcomes.

The bottom line

Psilocybin-assisted therapy has a real and clinically meaningful short-term treatment signal for some carefully screened adults with treatment-resistant depression. Confidence is high that short-term improvement occurs in structured settings, but lower on how much of the effect comes from the drug itself, how long it lasts, whether it prevents relapse and whether it is better than established treatments.

For now, it is best described as promising, not definitive. The evidence supports psilocybin as part of a closely supervised therapeutic package—not yet as a broadly proven, durable treatment ready for routine use. Important uncertainty also remains over unresolved conflict-of-interest classifications, alongside the trial-design problems that future confirmatory studies must address.